<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01366703</url>
  </required_header>
  <id_info>
    <org_study_id>pharao multicentre study</org_study_id>
    <nct_id>NCT01366703</nct_id>
  </id_info>
  <brief_title>Optimized Heart Failure Therapy Through Continuous Monitoring</brief_title>
  <acronym>pharao</acronym>
  <official_title>Optimized Heart Failure Therapy Through Continuous Monitoring. The PHARAO Multi-centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kennemer Gasthuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kennemer Gasthuis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with heart failure have a high incidence of atrial fibrillation (AF)and re-admission
      for heart failure. New methods have been developed to continuously monitor arrhythmia's and
      heart failure parameters. One such method is implantation of an implantable loop recorder.
      Also home-monitoring is available for continuous monitoring and information sending to the
      treating physicians, with improving detection of atrial fibrillation (AF) and/or other sever
      arrhythmia's we hope to improve patient care.

      Objective of the study:

      To investigate the clinical efficacy in detecting clinically relevant arrhythmia's
      (especially AF) of the Reveal XT in patients with mild to moderate heart failure and elevated
      risk factor for stroke and transient ischemic attack (TIA)(CHADS-score &gt;2), currently not
      treated with oral anticoagulation (OAC).

      Study design:

      In 50 stable sinus rhythm (no known AF)patients with New York health Association (NYHA class)
      2-3, a CHADS2-score&gt;2 and no indication for a implantable cardioverter-defibrillator (ICD) or
      pacemaker (PM) or OAC. Patients are put on home-monitoring (CareLink) and regular outward
      clinic visits. The number of relevant arrhythmia's detected will count for the primary
      endpoint. Also the number of medication changes and institution of OAC.

      Study population:

      50 stable patients, recruited from the outward clinic. NYHA class 2-3. Reveal XT
      implantation. CHADS2-score 2 or more. No indication for ICD/PM or OAC. No AF known.

      Primary study parameters/outcome of the study:

      Primary endpoints

        -  AF burden and AF episodes detected

        -  Detected other relevant arrhythmia's like SVT's (not AF) or ventricular tachycardias
           (VT's) or bradycardias

        -  % patients on OAC after 1 year follow-up

        -  Number of clinically relevant patient activated events

        -  Number of treatment policy changes based on the Reveal XT

      Secondary study parameters/outcome of the study

        -  specificity of AF detection algorithm by the Reveal

        -  Predictive value of the cardiac Compass data to predict worsening heart failure
           episodes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      no additional description needed
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>registered arrhythmias with implantable loop recorder during follow-up period</measure>
    <time_frame>1 year follow-up after last included patient</time_frame>
    <description>Primary study parameters/outcome of the study:
AF burden en AF episodes detected
Detected other relevant arrhythmia's like supraventricular tachycardia's (SVT's, not AF) or ventricular tachycardia's (VT's) or bradycardias
% patiÃ«nts on OAC after 1 year follow-up
Number of clinically relevant patient activated events
Number of treatment policy changes based on the Reveal XT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prediction of worsening heart failure through cardiac compass</measure>
    <time_frame>during follow-up (1 year after last included patient)</time_frame>
    <description>Predective value of the cardiac Compass data to predict worsening heart failure episodes.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>heart failure patients</arm_group_label>
    <description>stable heart failure patients, NYHA 1-2, EF &gt; 35%, no AF, No OAC, CHADS score &gt;2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>implantable loop recorder Medtronic reveal XT Full view</intervention_name>
    <description>Medtronic Reveal implantable loop recorder with home-monitoring using carelink will be implanted in every patient and used to continuously monitor the patients during follow-up to detect symptomatic and asymptomatic arrythmias during follow-up</description>
    <arm_group_label>heart failure patients</arm_group_label>
    <other_name>Medtronic reveal XT Full view</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        50 patients with stable heart failure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  EF &gt; 35%

          -  NYHA 2-3

          -  No AF documented

          -  Not on OAC

        Exclusion Criteria:

          -  use of OAC

          -  documented AF &gt; 30 sec

          -  planned or actual PM/ICD

          -  life-expectancy &lt; 1 year

          -  no informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>raymond tukkie, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kennemer Gasthuis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>raymond tukkie, MD PhD</last_name>
    <phone>+31 23 5453545</phone>
    <email>tukkie@kg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Tieleman, MD PhD</last_name>
    <phone>+31 50 5245245</phone>
    <email>r.tieleman@mzh.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rijnstate ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hans bosker, MD PhD</last_name>
      <email>hbosker@alysis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ype Tuininga, MD PhD</last_name>
      <email>y.s.tuininga@dz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Tieleman, MD PhD</last_name>
      <email>r.tieleman@mzh.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kennemer gasthuis</name>
      <address>
        <city>Haarlem</city>
        <zip>2000 AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>raymond tukkie, MD PhD</last_name>
      <phone>+31 23 5453545</phone>
      <email>tukkie@kg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Bob van Vlies, MD PhD</last_name>
      <phone>+31 23 5453545</phone>
      <email>vlies@kg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>raymond tukkie, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnland Ziekenhuis</name>
      <address>
        <city>Leiderdorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Kirchhof, MD PhD</last_name>
      <email>ch.kirchhof@orange.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2011</study_first_posted>
  <last_update_submitted>May 12, 2012</last_update_submitted>
  <last_update_submitted_qc>May 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kennemer Gasthuis</investigator_affiliation>
    <investigator_full_name>Dr. R. Tukkie MD PhD FESC</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>implantable loop recorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

